Stock Option

EuBiologics Co., Ltd.

206650·KOSDAQ·13 grants

Shares granted, cumulative
2,032,500shares
Next lockup release
—

Against the share price

At the 2026-08-18 close
KRW
+0.22%
Shares with a reason to exercise
510,000 shares
1.39% of shares outstanding
Sellable right now
510,000 shares
100% of the shares with a reason to exercise
Unrealized paper gain (to the employees)
₩1.3B

Potential dilution

3.71%Against the 15% cap

Shares by strike price

  • ₩48,850160K shares
  • ₩26,380255K shares
  • ₩24,940100K shares
  • ₩22,680205K shares
  • ₩11,860133K shares
  • ₩9,150Latest price
  • ₩8,160130K shares
  • ₩6,080380K shares

Below the line (strike < Latest price) sits above the strike price: 510K shares, 37% of the shares still inside their exercise window.

Exercise deadline within a yearD-217Earliest deadline 2027-03-25

The paper gain on 380,000 shares sitting above the strike price — ₩1.2B — disappears unless they are exercised by the deadline. Among the options whose lockup has ended, this is the part whose timing is pinned down.

See every approaching deadline

Options the share price has risen past gain a reason to be exercised and sold once the lockup ends. Filings do not show what has already been exercised or forfeited, so these figures are on a cumulative grants basis and the shares actually outstanding may be fewer.

Share price vs. strike price

A strike price is fixed on the grant date; only the share price moves. Where the price line crosses a dashed line is when that block of options first had a reason to be exercised.

Close ₩9,1502025-08-14 ~ 2026-08-18
  • Strike ₩6,080380K sharesabove
  • Strike ₩26,380255K shares
  • Strike ₩22,680205K shares
  • Strike ₩48,850160K shares

Recipients by role

1.4MShares granted
  • Registered director2 people4%
  • Unregistered officer6 people10%
  • Employee57 people55%
  • Other · unknown43 people31%

Sorted from the relation text written in the filings (108 recipients). Officers of affiliates and subsidiaries are counted as unregistered officers. This company reported many recipients under a lumped label such as “executives and employees”, or left the field blank, so the breakdown is limited.

Shares granted by year

220K
150K
300K
380K
365K
355K
130K
133K
'17
'18
'19
'20
'21
'22
'23
'24

Cumulative grants per recipient

16 named · 68 withheld
Largest holder정종호Registered director
Top holder 7.2%Top 3 7.2%
RecipientShares, cumulativePaper gain
50,0007.2%—
00.0%—
00.0%—
00.0%—
00.0%—
00.0%—
00.0%—
00.0%—
00.0%—
00.0%—

Recipients granted less than 10 in 10,000 of total shares issued have their names withheld under the disclosure rules; they cannot be split apart, so they are grouped into one row. Rows that pack several people onto one line, such as “OOO and 6 others”, are grouped there too, with the headcount read from that text — the split between them is never disclosed, so “my share” can only be prefilled with the per-person average. Filings carry no employee number or year of birth, so people with the same name are added together as one. “Exercisable” counts shares whose lockup has already ended, and any paper gain accrues to the employees holding the options.

Every figure here is parsed mechanically from the original DART filing (document.xml). “Exercise starts (estimated)” means the filing did not state an exercise period, so the date is the grant date plus two years under Article 340-2(4) of the Korean Commercial Act and may differ from the actual terms. Always read the original filing before making any decision.